RU2018129962A3 - - Google Patents

Info

Publication number: RU2018129962A3
Authority: RU; Russia

Application number

RU2018129962A

Other versions

RU2018129962A (ru

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-01-20

Filing date

2017-01-20

Publication date

2020-06-22

2017-01-20 Application filed filed Critical

2020-02-20 Publication of RU2018129962A publication Critical patent/RU2018129962A/ru

2020-06-22 Publication of RU2018129962A3 publication Critical patent/RU2018129962A3/ru

2022-02-09 Application granted granted Critical

2022-02-09 Publication of RU2766190C2 publication Critical patent/RU2766190C2/ru

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Wood Science & Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Hematology (AREA)
Oncology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

RU2018129962A 2016-01-20 2017-01-20 Композиции антител к ror1 и соответствующие способы RU2766190C2 (ru)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662280843P	2016-01-20	2016-01-20
US62/280,843		2016-01-20
PCT/US2017/014311 WO2017127664A1 (en)	2016-01-20	2017-01-20	Ror1 antibody compositions and related methods

Publications (3)

Publication Number	Publication Date
RU2018129962A RU2018129962A (ru)	2020-02-20
RU2018129962A3 true RU2018129962A3 (ru)	2020-06-22
RU2766190C2 RU2766190C2 (ru)	2022-02-09

Family

ID=57966152

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2018129962A RU2766190C2 (ru)	2016-01-20	2017-01-20	Композиции антител к ror1 и соответствующие способы

Country Status (16)

Country	Link
US (3)	US10618959B2 (ru)
EP (1)	EP3405496B1 (ru)
JP (1)	JP7000660B2 (ru)
KR (1)	KR20180101554A (ru)
CN (1)	CN108848669B (ru)
AU (1)	AU2017210327A1 (ru)
BR (1)	BR112018014615A2 (ru)
CA (1)	CA3011815A1 (ru)
CL (1)	CL2018001971A1 (ru)
IL (1)	IL260689B2 (ru)
MX (1)	MX2018008926A (ru)
PH (1)	PH12018501554A1 (ru)
RU (1)	RU2766190C2 (ru)
SG (1)	SG11201806120WA (ru)
UA (1)	UA125718C2 (ru)
WO (1)	WO2017127664A1 (ru)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20180069067A (ko)	2015-10-30	2018-06-22	엔비이-테라퓨틱스 아게	안티-ror1 항체
CA3006249A1 (en)	2015-11-25	2017-06-01	Legochem Biosciences, Inc.	Antibody-drug conjugates comprising branched linkers and methods related thereto
CN108848669B (zh)	2016-01-20	2022-06-07	斯克利普斯研究所	Ror1抗体组合物和相关方法
IL269535B2 (en)	2017-03-29	2024-11-01	Ligachem Biosciences Inc	Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
JP6983909B2 (ja)	2017-04-28	2021-12-17	ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク	ヒト化標的化ドメインを有するｒｏｒ１特異的キメラ抗原受容体（ｃａｒ）
WO2018237335A1 (en) *	2017-06-23	2018-12-27	VelosBio Inc.	IMMUNOCONJUGUATED ROR1 ANTIBODIES
GB201710838D0 (en)	2017-07-05	2017-08-16	Ucl Business Plc	Bispecific antibodies
GB201710836D0 (en)	2017-07-05	2017-08-16	Ucl Business Plc	ROR1 Car T-Cells
GB201710835D0 (en)	2017-07-05	2017-08-16	Ucl Business Plc	ROR1 Antibodies
CA3071212C (en) *	2017-08-07	2023-12-12	Nbe-Therapeutics Ag	Anthracycline-based antibody drug conjugates having high in vivo tolerability
WO2019090110A1 (en)	2017-11-03	2019-05-09	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-ror1 immunotherapy
GB201721802D0 (en)	2017-12-22	2018-02-07	Almac Discovery Ltd	Ror1-specific antigen binding molecules
WO2020018964A1 (en)	2018-07-20	2020-01-23	Fred Hutchinson Cancer Research Center	Compositions and methods for controlled expression of antigen-specific receptors
EP3636284A1 (en) *	2018-10-11	2020-04-15	NBE Therapeutics AG	Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications
DK3883966T5 (da)	2018-12-21	2024-08-05	Ose Immunotherapeutics	Humaniseret anti-human-pd-1-antistof
US20230071889A1 (en)	2018-12-21	2023-03-09	Ose Immunotherapeutics	Bifunctional anti-pd-1/il-7 molecule
US20220025050A1 (en)	2018-12-21	2022-01-27	Ose Immunotherapeutics	Bifunctional molecule directed against human pd-1
CA3122914A1 (en)	2018-12-21	2020-06-25	Ose Immunotherapeutics	Bifunctional anti-pd-1/sirp.alpha. molecule
US20220089758A1 (en) *	2019-01-22	2022-03-24	Revmab Biosciences Usa, Inc.	Novel anti-cd40 antibodies
CN113365660A (zh)	2019-01-29	2021-09-07	朱诺治疗学股份有限公司	对受体酪氨酸激酶样孤儿受体1(ror1)具特异性的抗体及嵌合抗原受体
JP2022523740A (ja) *	2019-02-01	2022-04-26	ベロスビオ・インコーポレイテッド	Ｒｏｒ１抗体イムノコンジュゲートによる癌の治療
WO2020165374A1 (en)	2019-02-14	2020-08-20	Ose Immunotherapeutics	Bifunctional molecule comprising il-15ra
CN111286512A (zh) *	2019-06-05	2020-06-16	南京艾德免疫治疗研究院有限公司	靶向人源化酪氨酸激酶孤儿受体1的嵌合抗原受体及其用途
KR20210028544A (ko) *	2019-09-04	2021-03-12	주식회사 레고켐 바이오사이언스	인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
US12441795B2 (en) *	2019-09-27	2025-10-14	Nanjing Immunophage Biotech Co., Ltd.	Anti-ROR1 antibodies and preparation method and uses thereof
CA3166286A1 (en) *	2020-02-07	2021-08-12	Jeffry D. Watkins	Anti-ror1 antibodies and compositions
JP2023542497A (ja) *	2020-09-11	2023-10-10	アレクシオンファーマシューティカルズ，インコーポレイテッド	抗セルロプラスミン抗体及びその使用
GB202020154D0 (en)	2020-12-18	2021-02-03	Almac Discovery Ltd	ROR1-specific variant antigen binding molecules
KR20230146053A (ko) *	2021-02-12	2023-10-18	베링거 인겔하임 인터내셔날 게엠베하	보체 c3 항원 결합 단백질
EP4298120A1 (en)	2021-02-25	2024-01-03	Lyell Immunopharma, Inc.	Ror1 targeting chimeric antigen receptor
US11806405B1 (en)	2021-07-19	2023-11-07	Zeno Management, Inc.	Immunoconjugates and methods
IL310972A (en) *	2021-09-12	2024-04-01	Immunorizon Ltd	Antibodies against ROR1 and their uses
AU2022376953A1 (en)	2021-10-28	2024-05-02	Lyell Immunopharma, Inc.	Methods for culturing cells expressing ror1-binding protein
WO2023183950A2 (en) *	2022-03-25	2023-09-28	Board Of Regents, The University Of Texas System	Anti-ror1 antibody and chimeric antigen receptor and methods of use thereof
US20240092941A1 (en) *	2022-07-11	2024-03-21	Fred Hutchinson Cancer Center	Single-domain antibodies that bind ror1
JP2025526427A (ja) *	2022-07-26	2025-08-13	エイムドバイオインコーポレイテッド	抗ｒｏｒ１抗体及びその用途
CN119907807A (zh) *	2022-08-11	2025-04-29	翰森生物有限责任公司	配体-细胞毒性药物偶联物及其药物用途
WO2024064952A1 (en)	2022-09-23	2024-03-28	Lyell Immunopharma, Inc.	Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en)	2022-09-23	2024-03-28	Lyell Immunopharma, Inc.	Methods for culturing nr4a-deficient cells
WO2024077174A1 (en)	2022-10-05	2024-04-11	Lyell Immunopharma, Inc.	Methods for culturing nr4a-deficient cells
CN118878679A (zh) *	2023-04-30	2024-11-01	泰诚思(上海)生物医药有限公司	hROR1的抗原结合蛋白及其用途
WO2025217398A1 (en)	2024-04-10	2025-10-16	Lyell Immunopharma, Inc.	Methods for culturing cells with improved culture medium
CN119431591B (zh) *	2024-12-16	2025-08-05	无锡傲锐东源生物科技有限公司	抗人psp蛋白的单克隆抗体及其应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3854480A (en)	1969-04-01	1974-12-17	Alza Corp	Drug-delivery system
US3832253A (en)	1973-03-21	1974-08-27	Baxter Laboratories Inc	Method of making an inflatable balloon catheter
US4458066A (en)	1980-02-29	1984-07-03	University Patents, Inc.	Process for preparing polynucleotides
US4667014A (en)	1983-03-07	1987-05-19	Syntex (U.S.A.) Inc.	Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en)	1982-12-03	1984-06-05	Syntex (U.S.A.) Inc.	Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en)	1983-05-13	1986-02-11	Societe Des Produits Nestle S.A.	Food process
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5075109A (en)	1986-10-24	1991-12-24	Southern Research Institute	Method of potentiating an immune response
JPH04167172A (ja)	1990-10-31	1992-06-15	Nec Corp	ベクトルプロセッサ
US20030113762A1 (en)	2001-08-17	2003-06-19	Warrington Janet A.	Gleason grade 4/5 prostate cancer genes
CN103555677B (zh)	2001-11-13	2018-01-30	宾夕法尼亚大学托管会	检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
EP1509537B9 (en)	2002-04-26	2007-11-14	Gilead Sciences, Inc.	Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds and the compounds as such
ES2369542T3 (es)	2002-07-31	2011-12-01	Seattle Genetics, Inc.	Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
US20080318212A1 (en)	2004-04-06	2008-12-25	Wilson Cindy A	Orphan Receptor Tyrosine Kinase as a Target in Breast Cancer
WO2007051077A2 (en)	2005-10-28	2007-05-03	The Regents Of The University Of California	Methods and compounds for lymphoma cell detection and isolation
WO2008103849A2 (en)	2007-02-21	2008-08-28	The Regents Of The University Of California	Methods and compounds for lymphoma cell detection and isolation
WO2007146957A2 (en)	2006-06-13	2007-12-21	Irm Llc	Ror1 as a therapeutic target for lung cancer
JP2010511382A (ja)	2006-12-01	2010-04-15	エージェンシーフォーサイエンス，テクノロジーアンドリサーチ	癌関連タンパク質キナーゼ
WO2008076868A2 (en)	2006-12-18	2008-06-26	Abbott Laboratories	Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)
WO2008122039A2 (en)	2007-04-02	2008-10-09	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Selenocysteine mediated hybrid antibody molecules
ES2547552T3 (es)	2008-02-01	2015-10-07	Genentech, Inc.	Metabolito de nemorrubicina y reactivos análogos, conjugados anticuerpo-fármaco y métodos
KR100994996B1 (ko)	2008-08-06	2010-11-18	한국과학기술연구원	페난트렌 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
CA2745460C (en) *	2008-12-19	2021-07-13	Macrogenics, Inc.	Covalent diabodies and uses thereof
CA2759733C (en)	2009-04-23	2019-09-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-human ror1 antibodies
US20120282177A1 (en)	2009-11-02	2012-11-08	Christian Rohlff	ROR1 as Therapeutic and Diagnostic Target
AU2010315057B2 (en)	2009-11-05	2015-05-14	Sloan Kettering Institute For Cancer Research	Catenae: serosal cancer stem cells
MY172005A (en)	2009-12-07	2019-11-11	Univ Georgia	Pyridinone hydroxycyclopentyl carboxamides : hiv integrase inhibators with therapeutic applications
ES2635316T3 (es)	2009-12-18	2017-10-03	Kancera Ab	Anticuerpos contra ROR1 que pueden inducir muerte celular de LLC
US9242014B2 (en)	2010-06-15	2016-01-26	The Regents Of The University Of California	Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
US9163258B2 (en)	2010-07-23	2015-10-20	Fred Hutchinson Cancer Research Center	Method for the treatment of obesity
EP2621954A1 (en)	2010-10-01	2013-08-07	Oxford Biotherapeutics Ltd.	Anti-rori antibodies
AU2011336650B2 (en) *	2010-12-01	2016-12-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Chimeric rabbit/human ROR1 antibodies
JP6008864B2 (ja)	2010-12-02	2016-10-19	ナーヴィアノメディカルサイエンシズエス．アール．エル．	モルホリニルアントラサイクリン誘導体の調製方法
GB201020995D0 (en) *	2010-12-10	2011-01-26	Bioinvent Int Ab	Biological materials and uses thereof
EP2649098B1 (en)	2010-12-10	2017-11-22	Kancera AB	Antibodies against ror1 and their uses
DK2663579T3 (en)	2011-01-14	2017-07-31	Univ California	THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
US20130131139A1 (en)	2011-11-17	2013-05-23	Oregon Health & Science University	Ror1 as a gene target in acute lymphoblastic leukemia
ES2528892T3 (es)	2012-07-30	2015-02-13	Nbe-Therapeutics Llc	Identificación mediada por trasposición de proteínas de unión o funcionales específicas
IL269270B (en)	2012-08-20	2022-07-01	Hutchinson Fred Cancer Res	Method and preparations for cellular immunotherapy
WO2014031174A1 (en)	2012-08-24	2014-02-27	The Regents Of The University Of California	Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
US10786532B2 (en)	2012-10-02	2020-09-29	Versiti Blood Research Institute Foundation, Inc.	Method of providing cellular therapy using modified natural killer cells or T lymphocytes
EP2777714A1 (en)	2013-03-15	2014-09-17	NBE-Therapeutics LLC	Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
EP2789630A1 (en)	2013-04-09	2014-10-15	EngMab AG	Bispecific antibodies against CD3e and ROR1
WO2015113110A1 (en)	2014-01-29	2015-08-06	University Of Western Sydney	A method for the purification of eye lens cells
EP3593812A3 (en)	2014-03-15	2020-05-27	Novartis AG	Treatment of cancer using chimeric antigen receptor
ES2867224T3 (es)	2014-04-10	2021-10-20	Seattle Childrens Hospital Dba Seattle Childrens Res Inst	Etiquetas genéticas transgénicas y métodos de uso
SMT202000355T1 (it)	2014-04-25	2020-09-10	Bluebird Bio Inc	Metodi migliorati per produrre terapie con cellule adottive
WO2015184207A1 (en)	2014-05-29	2015-12-03	Macrogenics, Inc.	Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
BR112017001821A2 (pt)	2014-07-29	2017-11-21	Cellectis	receptores de antígenos quiméricos específicos de ror1 (ntrkr1) para imunoterapia de câncer
CA2956482A1 (en)	2014-07-31	2016-02-04	Cellectis	Ror1 specific multi-chain chimeric antigen receptor
ES2777305T5 (en)	2014-09-04	2025-09-30	Cellectis	Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
JP2017536341A (ja)	2014-10-09	2017-12-07	エンクマフアーゲー	卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体
CA2963692A1 (en)	2014-10-09	2016-04-14	Engmab Ag	Bispecific antibodies against cd3epsilon and ror1
HK1243631A1 (zh)	2014-10-27	2018-07-20	Fred Hutchinson Cancer Research Center	用於提高过继细胞免疫疗法效力的组合物和方法
WO2016094373A1 (en)	2014-12-08	2016-06-16	George Mason University	Methods for breast cancer treatment
WO2016094873A2 (en)	2014-12-12	2016-06-16	Emergent Product Development Seattle, Llc	Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
SG10202101603TA (en)	2014-12-23	2021-03-30	Nbe Therapeutics Ag	Binding protein drug conjugates comprising anthracycline derivatives
FR3030807B1 (fr)	2014-12-23	2018-02-02	Thales	Procede non lineaire d'estimation d'un melange de signaux
WO2016142768A1 (en)	2015-03-10	2016-09-15	Eureka Therapeutics, Inc.	Ror2 antibody
CA2981751A1 (en)	2015-04-08	2016-10-13	Novartis Ag	Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
CA2983293C (en)	2015-04-24	2023-06-20	The Regents Of The University Of California	Modulators of ror1-ror2 binding
EP3298032A1 (en)	2015-05-18	2018-03-28	Bluebird Bio, Inc.	Anti-ror1 chimeric antigen receptors
HK1253507A1 (zh)	2015-05-18	2019-06-21	Eureka Therapeutics, Inc.	抗 ror1 抗體
WO2017053469A2 (en)	2015-09-21	2017-03-30	Aptevo Research And Development Llc	Cd3 binding polypeptides
KR20180069067A (ko)	2015-10-30	2018-06-22	엔비이-테라퓨틱스 아게	안티-ror1 항체
CN106918698B (zh)	2015-12-25	2019-11-22	广州瑞博奥生物科技有限公司	一种检测人受体酪氨酸激酶的磷酸化抗体芯片试剂盒
CN108848669B (zh)	2016-01-20	2022-06-07	斯克利普斯研究所	Ror1抗体组合物和相关方法
CA3011419A1 (en)	2016-01-22	2017-07-27	Janssen Biotech, Inc.	Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same
AU2017213844A1 (en)	2016-02-02	2018-08-02	Fred Hutchinson Cancer Center	Anti-ROR1 antibodies and uses thereof
UY37127A (es)	2016-02-17	2017-08-31	Macrogenics Inc	Moléculas de unión a ror1, y métodos de uso de las mismas
CA3071212C (en) *	2017-08-07	2023-12-12	Nbe-Therapeutics Ag	Anthracycline-based antibody drug conjugates having high in vivo tolerability

2017
- 2017-01-20 CN CN201780019846.1A patent/CN108848669B/zh active Active
- 2017-01-20 MX MX2018008926A patent/MX2018008926A/es unknown
- 2017-01-20 WO PCT/US2017/014311 patent/WO2017127664A1/en not_active Ceased
- 2017-01-20 SG SG11201806120WA patent/SG11201806120WA/en unknown
- 2017-01-20 JP JP2018537754A patent/JP7000660B2/ja active Active
- 2017-01-20 UA UAA201808044A patent/UA125718C2/uk unknown
- 2017-01-20 AU AU2017210327A patent/AU2017210327A1/en not_active Abandoned
- 2017-01-20 KR KR1020187023595A patent/KR20180101554A/ko not_active Ceased
- 2017-01-20 BR BR112018014615-3A patent/BR112018014615A2/pt not_active IP Right Cessation
- 2017-01-20 RU RU2018129962A patent/RU2766190C2/ru active
- 2017-01-20 CA CA3011815A patent/CA3011815A1/en active Pending
- 2017-01-20 EP EP17703552.4A patent/EP3405496B1/en active Active
2018
- 2018-07-19 US US16/040,244 patent/US10618959B2/en active Active
- 2018-07-19 PH PH12018501554A patent/PH12018501554A1/en unknown
- 2018-07-19 IL IL260689A patent/IL260689B2/en unknown
- 2018-07-20 CL CL2018001971A patent/CL2018001971A1/es unknown
2020
- 2020-02-28 US US16/805,102 patent/US11242388B2/en active Active
2021
- 2021-12-28 US US17/563,273 patent/US20220153839A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA3011815A1 (en)	2017-07-27
JP7000660B2 (ja)	2022-02-04
RU2018129962A (ru)	2020-02-20
US10618959B2 (en)	2020-04-14
AU2017210327A1 (en)	2018-08-09
EP3405496A1 (en)	2018-11-28
RU2766190C2 (ru)	2022-02-09
KR20180101554A (ko)	2018-09-12
US20180340026A1 (en)	2018-11-29
WO2017127664A1 (en)	2017-07-27
UA125718C2 (uk)	2022-05-25
JP2019509021A (ja)	2019-04-04
CN108848669A (zh)	2018-11-20
PH12018501554A1 (en)	2019-05-20
US20200299381A1 (en)	2020-09-24
IL260689A (en)	2022-12-01
IL260689B2 (en)	2023-04-01
MX2018008926A (es)	2019-01-10
SG11201806120WA (en)	2018-08-30
US20220153839A1 (en)	2022-05-19
CL2018001971A1 (es)	2018-12-21
EP3405496B1 (en)	2023-10-25
CN108848669B (zh)	2022-06-07
BR112018014615A2 (pt)	2018-12-11
US11242388B2 (en)	2022-02-08

Publication	Publication Date	Title
BR112019001667A2 (ru)	2019-07-23
BR212018070320U2 (ru)	2019-03-12
BR112018071172A2 (ru)	2023-07-25
CN303581110S (ru)	2016-02-03
CN303537496S (ru)	2016-01-06
BY21942C1 (ru)	2018-06-30
CN303535544S (ru)	2016-01-06
CN303535546S (ru)	2016-01-06
CN303536049S (ru)	2016-01-06
CN303536130S (ru)	2016-01-06
CN303536205S (ru)	2016-01-06
CN303536215S (ru)	2016-01-06
CN303536239S (ru)	2016-01-06
CN303536379S (ru)	2016-01-06
CN303536489S (ru)	2016-01-06
CN303536542S (ru)	2016-01-06
CN303536549S (ru)	2016-01-06
CN303536579S (ru)	2016-01-06
CN303536594S (ru)	2016-01-06
CN303536597S (ru)	2016-01-06
CN303537277S (ru)	2016-01-06
CN303537328S (ru)	2016-01-06
CN303537330S (ru)	2016-01-06
CN303537400S (ru)	2016-01-06
CN303537415S (ru)	2016-01-06